Literature DB >> 15464386

Synthesis and preclinical evaluation of the choline transport tracer deshydroxy-[18F]fluorocholine ([18F]dOC).

G Henriksen1, M Herz, A Hauser, M Schwaiger, H-J Wester.   

Abstract

11C-labeled choline ([11C]CHO) and 18F-fluorinated choline analogues have been demonstrated to be valuable tracers for in vivo imaging of neoplasms by means of positron emission tomography (PET). The objective of the present study was to evaluate whether deshydroxy-[18F]fluorocholine, ([18F]dOC), a non-metabolizable [18F]fluorinated choline analogue, can serve as a surrogate for cholines that are able to be phosphorylated and thus allow PET-imaging solely by addressing the choline transport system. The specificity of uptake of [18F]dOC was compared with that of [11C]choline ([11C]CHO) in cultured rat pancreatic carcinoma and PC-3 human prostate cancer cells in vitro. In addition, biodistribution of [18F]dOC and [11C]CHO was compared in AR42J- and PC-3 tumor bearing mice. The in vitro studies revealed that membrane transport of both compounds can be inhibited in a concentration dependent manner by similar concentrations of cold choline (IC50 [18F]dOC= 11 microM; IC50 [11C]CHO=13 microM. In vitro studies with PC-3 and AR42J cells revealed that the internalized fraction of [18F]dOC after 5 min incubation time is comparable to that of [11C]CHO, whereas the uptake of [11C]CHO was superior after 20 min incubation time. As for [11C]CHO, kidney and liver were also the primary sites of uptake for [18F]dOC in vivo. Biodistribution data after simultaneous injection of both tracers into AR42J tumor bearing mice revealed slightly higher tumor uptake for [18F]dOC at 10 min post-injection, whereas [11C]CHO uptake was higher at later time points. In conclusion, [18F]dOC is taken up into AR42J rat pancreatic carcinoma and PC-3 human prostate cancer cells by a choline specific transport system. Similar transport rates of [18F]dOC and [11C]CHO result in comparable cellular uptake levels at early time points. In contrast to [18F]dOC, which is transported but not intracellularly trapped, the choline kinase substrate [11C]CHO is transported into tumor cells and retained. Thus, the signal obtained by imaging early after injection is mainly reflecting transport, whereas a valid quantification of choline kinase activity needs imaging at later time points. Further studies have to clarify whether quantification of the transport capacity or the choline kinase activity result in a better pathophysiological correlate and thus is the more useful process for tumor characterization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464386     DOI: 10.1016/j.nucmedbio.2004.05.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  11 in total

1.  11C-Choline Pharmacokinetics in Recurrent Prostate Cancer.

Authors:  Milan Grkovski; Karem Gharzeddine; Peter Sawan; Heiko Schöder; Laure Michaud; Wolfgang A Weber; John L Humm
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

2.  Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.

Authors:  Sarah Marie Schwarzenböck; Philipp Schmeja; Jens Kurth; Michael Souvatzoglou; Roman Nawroth; Uwe Treiber; Guenther Kundt; Sandra Berndt; Keith Graham; Reingard Senekowitsch-Schmidtke; Markus Schwaiger; Sibylle I Ziegler; Ludger Dinkelborg; Hans-Jürgen Wester; Bernd Joachim Krause
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

Review 3.  Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.

Authors:  Xiao-Yi Wang; Feng Yang; Chen Jin; De-Liang Fu
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Translational Molecular Imaging of Prostate Cancer.

Authors:  Ana P Kiess; Steve Y Cho; Martin G Pomper
Journal:  Curr Radiol Rep       Date:  2013-09-01

5.  Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.

Authors:  Nicolas Spaeth; Matthias T Wyss; Jens Pahnke; Gregoire Biollaz; Amelie Lutz; Kerstin Goepfert; Gerrit Westera; Valerie Treyer; Bruno Weber; Alfred Buck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-15       Impact factor: 9.236

Review 6.  Radionuclide imaging: a molecular key to the atherosclerotic plaque.

Authors:  Harald F Langer; Roland Haubner; Bernd J Pichler; Meinrad Gawaz
Journal:  J Am Coll Cardiol       Date:  2008-07-01       Impact factor: 24.094

7.  Comparison of [¹¹C]choline ([¹¹C]CHO) and S(+)-β-methyl-[¹¹C]choline ([¹¹C]SMC) as imaging probes for prostate cancer in a PC-3 prostate cancer xenograft model.

Authors:  Sarah Marie Schwarzenböck; Jana Gertz; Michael Souvatzoglou; Jens Kurth; David Sachs; Roman Nawroth; Uwe Treiber; Tibor Schuster; Reingard Senekowitsch-Schmidtke; Markus Schwaiger; Sibylle Ilse Ziegler; Gjermund Henriksen; Hans-Jürgen Wester; Bernd Joachim Krause
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

8.  Usefulness of 11C-choline positron emission tomography for genital chlamydial infection assessment in a BALB/c murine model.

Authors:  Antonella Marangoni; Cristina Nanni; Carmelo Quarta; Claudio Foschi; Incoronata Russo; Paola Nardini; Antonietta D'Errico; Francesca Rosini; Alice Ferretti; Rita Aldini; Roberto Cevenini; Domenico Rubello
Journal:  Mol Imaging Biol       Date:  2013-08       Impact factor: 3.488

9.  Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans--first results.

Authors:  Jan Bucerius; Jörn Schmaljohann; Ingrid Böhm; Holger Palmedo; Stefan Guhlke; Klaus Tiemann; Hans Heinz Schild; Hans-Jürgen Biersack; Christoph Manka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-06       Impact factor: 9.236

10.  The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.

Authors:  Mustafa Takesh
Journal:  ISRN Oncol       Date:  2012-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.